Department of Molecular Bioscience, College of Biomedical Science, and Institute of Bioscience & Biotechnology, Kangwon National University, Chuncheon 200-701, Korea.
BMB Rep. 2014 Jul;47(7):369-75. doi: 10.5483/bmbrep.2014.47.7.086.
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic bioactive peptide that was first isolated from an ovine hypothalamus in 1989. PACAP belongs to the secretin/glucagon/vasoactive intestinal polypeptide (VIP) superfamily. PACAP is widely distributed in the central and peripheral nervous systems and acts as a neurotransmitter, neuromodulator, and neurotrophic factor via three major receptors (PAC1, VPAC1, and VPAC2). Recent studies have shown a neuroprotective role of PACAP using in vitro and in vivo models. In this review, we briefly summarize the current findings on the neurotrophic and neuroprotective effects of PACAP in different brain injury models, such as cerebral ischemia, Parkinson's disease (PD), and Alzheimer's disease (AD). This review will provide information for the future development of therapeutic strategies in treatment of these neurodegenerative diseases.
垂体腺苷酸环化酶激活肽（PACAP）是一种具有多种生物活性的肽，于 1989 年首次从绵羊下丘脑分离得到。PACAP 属于分泌素/胰高血糖素/血管活性肠肽（VIP）超家族。PACAP 广泛分布于中枢和外周神经系统，通过三种主要受体（PAC1、VPAC1 和 VPAC2）发挥神经递质、神经调质和神经营养因子的作用。最近的研究表明，PACAP 在体外和体内模型中具有神经保护作用。在这篇综述中，我们简要总结了 PACAP 在不同脑损伤模型（如脑缺血、帕金森病（PD）和阿尔茨海默病（AD））中的神经营养和神经保护作用的最新发现。这篇综述将为未来开发治疗这些神经退行性疾病的治疗策略提供信息。
